WO1997026910A3 - Tumour vaccine for immunotherapy of malignant tumours - Google Patents

Tumour vaccine for immunotherapy of malignant tumours Download PDF

Info

Publication number
WO1997026910A3
WO1997026910A3 PCT/DE1997/000172 DE9700172W WO9726910A3 WO 1997026910 A3 WO1997026910 A3 WO 1997026910A3 DE 9700172 W DE9700172 W DE 9700172W WO 9726910 A3 WO9726910 A3 WO 9726910A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
immunotherapy
malignant tumours
tumour vaccine
thermal shock
Prior art date
Application number
PCT/DE1997/000172
Other languages
German (de)
French (fr)
Other versions
WO1997026910A2 (en
Inventor
Juergen Milleck
Werner Reichardt
Rainer Benndorf
Windfried Liebrich
Peter Schlag
Original Assignee
Max Delbrueck Centrum
Juergen Milleck
Werner Reichardt
Rainer Benndorf
Windfried Liebrich
Peter Schlag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19602985A external-priority patent/DE19602985A1/en
Priority claimed from DE19604380A external-priority patent/DE19604380A1/en
Application filed by Max Delbrueck Centrum, Juergen Milleck, Werner Reichardt, Rainer Benndorf, Windfried Liebrich, Peter Schlag filed Critical Max Delbrueck Centrum
Publication of WO1997026910A2 publication Critical patent/WO1997026910A2/en
Publication of WO1997026910A3 publication Critical patent/WO1997026910A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Abstract

The invention concerns a tumour vaccine in which the immunogenicity of tumour cells, tumour associated antigens or antigen partial structures are reinforced through genetic modification or through chemical bonding to an exogenous thermal shock protein. The use of microbial thermal shock proteins or their genes is preferred which are derived from mycobacteria, Escherichia coli or from Chlamydia trachomatis.
PCT/DE1997/000172 1996-01-27 1997-01-27 Tumour vaccine for immunotherapy of malignant tumours WO1997026910A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19602985A DE19602985A1 (en) 1996-01-27 1996-01-27 Tumour vaccine for treatment of, e.g., carcinoma melanoma or leukaemia
DE19602985.6 1996-01-27
DE19604380A DE19604380A1 (en) 1996-02-07 1996-02-07 Tumour vaccine for treatment of, e.g. carcinoma, lymphoma or leukaemia
DE19604380.8 1996-02-07

Publications (2)

Publication Number Publication Date
WO1997026910A2 WO1997026910A2 (en) 1997-07-31
WO1997026910A3 true WO1997026910A3 (en) 1997-10-02

Family

ID=26022430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000172 WO1997026910A2 (en) 1996-01-27 1997-01-27 Tumour vaccine for immunotherapy of malignant tumours

Country Status (1)

Country Link
WO (1) WO1997026910A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0700445T3 (en) 1993-06-04 2002-05-13 Whitehead Biomedical Inst Stress proteins and their applications
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
WO1997006821A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
PT941315E (en) * 1996-11-26 2006-06-30 Stressgen Biotechnologies Corp STRESS PROTEINS CONTAINING FUSEO PROTEINS TO INDUCE IMMUNE RESPONSE
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
NZ502568A (en) 1997-08-05 2003-01-31 Stressgen Biotechnologies Corp Compositions to enhance immune responses against HPV (human papilloma virus) protein antigens and against tumours exhibiting an HPV protein antigen
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
EP1829551B1 (en) 1998-02-20 2010-09-29 University of Miami Modified heat shock protein-antigenic peptide complex
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
EP1196772A2 (en) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
AU7743100A (en) 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EP1253939B1 (en) * 2000-01-14 2009-08-05 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
AU2001266694C1 (en) 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
KR20080075560A (en) 2000-06-26 2008-08-18 엔벤타 바이오파마슈티컬스 코포레이션 Human papilloma virus treatment
RU2295536C2 (en) 2001-02-05 2007-03-20 Стрессджен Байотекнолоджиз Корп. Composition based on hepatitis b virus (hbv) protein and stress protein and uses thereof
IL160511A0 (en) 2001-08-20 2004-07-25 Univ Connecticut Health Ct Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP3253876B1 (en) 2015-02-06 2020-11-04 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
EP3373961A4 (en) * 2015-11-10 2019-07-31 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011513A1 (en) * 1992-11-13 1994-05-26 Medical Research Council Heat shock proteins and the treatment of tumours

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011513A1 (en) * 1992-11-13 1994-05-26 Medical Research Council Heat shock proteins and the treatment of tumours

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CELIO L. SILVA ET AL.: "CHARACTERIZATION OF T CELLS THAT CONFER A HIGH DEGREE OF PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS IN MICE AFTER VACCINATION WITH TUMOR CELLS EXPRESSING MYCOBACTERIAL HSP65", INFECTION AND IMMUNITY, vol. 64, no. 7, July 1996 (1996-07-01), WASHINGTON US, pages 2400 - 2407, XP002037579 *
MICHAEL HEIKE ET AL.: "HEAT SHOCK PROTEIN-PEPTIDE COMPLEXES FOR USE IN VACCINES", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 60, August 1996 (1996-08-01), pages 153 - 158, XP002037580 *
NATHALIE E. BLACHERE ET AL.: "HEAT SHOCK PROTEIN VACCINES AGAINST CANCER", JOURNAL OF IMMUNOTHERAPY, vol. 14, November 1993 (1993-11-01), pages 352 - 356, XP002037576 *
NATHALIE E. BLACHERE ET AL.: "HEAT SHOCK PROTEIN-BASED CANCER VACCINES AND RELATED THOUGHTS ON IMMUNOGENICITY OF HUMAN TUMORS", SEMINARS IN CANCER BIOLOGY, vol. 6, December 1995 (1995-12-01), pages 349 - 355, XP002037577 *
PRAMOD K. SRIVASTAVA ET AL.: "HEAT SHOCK PROTEIN-PEPTIDE COMPLEXES IN CANCER IMMUNOTHERAPY", CURRENT OPINION IN IMMUNOLOGY, vol. 6, 1994, LONDON GB, pages 728 - 732, XP002037578 *
SATISH JINDAL: "HEAT SHOCK PROTEINS:APPLICATIONS IN HEALTH AND DISEASE", TRENDS IN BIOTECHNOLOGY, vol. 14, January 1996 (1996-01-01), CAMBRIDGE GB, pages 17 - 20, XP002037582 *
TAMÁS SCHWEIGHOFFER: "TUMOR CELLS EXPRESSING A RECALL ANTIGEN ARE POWERFUL CANCER VACCINES", EUR. J. IMMUNOL., vol. 26, November 1996 (1996-11-01), pages 2559 - 2564, XP002037581 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same

Also Published As

Publication number Publication date
WO1997026910A2 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
WO1997026910A3 (en) Tumour vaccine for immunotherapy of malignant tumours
AU7599500A (en) Novel gl50 molecules and uses therefor
DE69727966D1 (en) A CANCER-ASSOCIATED ANTIQUE-COATING ISOLATED NUCLEIC ACID MOLECULE, THE ANTIQUE ITSELF, AND THEIR USE
AU3431497A (en) DNA immunization against Chlaymdia infection
AU2590901A (en) Il-17 homologous polypeptides and therapeutic uses thereof
WO2000066067A3 (en) Ibd-associated microbial antigens and methods of using same
WO2000029428A3 (en) 5t4 tumour-associated antigen for use in tumour immunotherapy
WO2003042362A3 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO2002070538A3 (en) Narc8 programmed cell-death-associated molecules and uses thereof
WO2002000722A3 (en) Human calcium channels (48000; 52920) and uses thereof
WO2000075358A3 (en) Mammalian toll homologues and uses thereof
WO2001087978A3 (en) Human abc transporter and its use
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
AU2002320301A1 (en) Novel pgc-1 isoforms and uses therefor
WO1999051745A3 (en) Dna immunization against chlamydia infection
WO2002000718A3 (en) A human calcium channel protein and uses thereof
WO2002016591A3 (en) Human transporter family members and uses thereof
WO2002000859A3 (en) 46508, a novel human peptidyl-trna hydrolase family member and uses thereof
WO2003000894A9 (en) Polynucleotide vaccine
WO2001094390A3 (en) 52906, 33408, and 12189, potassium channel family members and uses thereof
WO2001079489A8 (en) 39228, a human alcohol dehydrogenase and uses therefor
WO2000031133A3 (en) Potassium channel interactors and uses therefor
WO2001083719A3 (en) 25692, a novel human o-methyltransferase family member and uses thereof
AU2001253258A1 (en) Human trp-like calcium channel protein-2 (tlcc-2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97526442

Format of ref document f/p: F